The Cardiology World Conference CARDIO 2024 takes place September 5 – 7, 2024, in Madrid, Spain.
The lecture of Thomas Bernd Dschietzig is about treatment of HFpEF and focuses on pre-clinical experiments and results with relaxin-2, explaining the bolus therapy and the signalling portfolio of the native peptide.
Relaxin-2 delivery reverses diastolic dysfunction, arrhythmia susceptibility, inflammation, and excess fibrosis.
Get a summary of the presentation here an view the whole presentation using this youtube link.
Relaxera is currently preparing a phase II clinical trial in HFpEF.